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Abstract: Sickle cell disease (SCD) is an inherited disorder of hemoglobin structure. The clinical
effects of the sickle gene are pleiotropic in nature causing multiple phenotypic expressions associated
with the various complications of the disease. The hallmark of the disease is pain that could be
acute, chronic, nociceptive, or neuropathic that could occur singly or in various combinations.
The acute vaso-occlusive painful crisis (VOC) is the most common cause of admissions to the
Emergency Department and/or the hospital. Although progress has been made in understanding the
pathophysiology of SCD as well as in developing preventive and curative therapies, effective pain
management continues to lag behind and depend mostly on the use of opioids. This review describes
the history of opioids from the ancient times of opium to the current use of the many controversial
opioids. In addition, the major cause of death of patients with SCD is the complications of the disease
itself and not the use of opioids. The use of opioids by patients with SCD has been stable over
the years. Judicious use of opioids to treat sickle cell pain according to available guidelines could
minimize the unnecessary suffering experienced by patients with SCD.
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1. Introduction
Sickle cell disease (SCD) is a complex genetic disorder caused by a missense mutation
in the human β globin gene (HBB) leading to the sickle hemoglobin (Hb) variant HbS.
Patients with SCD can be homozygous (HbSS) or heterozygous for the mutation (HbSC) [1].
HbS–β0-thalassemia is a form of SCD that is clinically similar in severity to HbSS, whereas
HbS-β+-thalassemia is a milder form of SCD. Sickle cell disease predominantly affects individuals of African descent and is the most common hemoglobinopathy, with approximately
300,000 new cases each year and millions of patients affected globally. In the United States,
there are more than 230,000 hospital admissions related to SCD annually at an economic
cost of $2.4 billion [2]. Acute episodes of pain, also commonly referred to as vaso-occlusive
crises (VOCs), are not only the primary presenting morbidity associated with SCD, but
also the most common cause of admission to the Emergency Department or Hospital in
approximately 95% of cases [3]. It is estimated that up to 100,000 patients in the USA have
SCD [2].
The major objective of this paper is to describe what the opioids really are and how
they came about over the years. Opium has been used in different countries and cultures
for millennia, but only in the last century, opioids related to or from opium came into
existence, including their related problems. It remains unclear how these opioids affected
SCD. The primary objective of this manuscript was not to have a detailed review about
sickle cell disease and its related basic and clinical aspects. Most of these aspects have
been described before, including by the NHLBI (National Heart, Lung and Blood Institute),
American Society of Hematology and others. In the following paragraph, some of these
aspects are described.
Management of sickle pain includes pharmacologic and nonpharmacological approaches. The former includes opioids, Nonsteroidal anti-inflammatory drugs (NSAIDs),
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The word “narcotic” is derived from the Greek “narkoun”, meaning “to benumb”,
and “narki”, meaning “numbness” or “stupor” [6]. As a noun, narcotic means (1) any drug

J. Clin. Med. 2021, 10, 438

3 of 16

that induces stupor, (2) a person addicted to narcotics or (3) anything that causes stupor [6].
It is important to note that “opioids” and “narcotics” are not synonymous. In common
usage, narcotic connotes addiction, drug-seeking behavior and association with abused
substances. It is advisable not to use this term in a pharmacologic context.
2. Historic Milestones: From Opium to Opioids
2.1. Mythology
In Greek mythology, Hypnos (Somnus in Roman mythology) was the god of sleep. He
slept in a cave in Hades with poppies growing at the entrance of the cave along with other
hypnotic plants. The words hypnosis, hypnotic and insomnia are derived from their Greek
and Roman names. Morpheus (god of dreams) was the eldest son of Hypnos. He had
wings to reach people who needed help in their dreams and to communicate the messages
of the gods to humans during sleep. He could take the form of any human in dreams.
Each sibling of Morpheus was a God of different kinds of dreams such as nightmares and
unrealistic dreams etc., including Phobetor (god of nightmares) and Phantasus (god of
imagination and fantasy). Ironically, these gods, in a way, depict or represent some of the
side-effects of opioids, including drowsiness, vivid dreams and fantasy dreams [6].
The Algea (Lupe, Ania and Achus) were the spirits who represent pain and suffering.
The origin of the term analgesia is from a compound word of “an” (no) and “algia”
(pain) [6].
2.2. Global Use of Opium
The Sumerians are credited for their use of opium in 3400 B.C. [7]. From Sumer,
opium spread to Assyria and later to Egypt [7]. The ancient Greek poem, the Odyssey,
mentions how familiar the Egyptian and Greek royalty were with opium [8]. The Egyptians
used it as a tonic for children with abdominal pain [7]. Dioscorides, a first-century Greek
physician-botanist, described how to collect opium from the unripe poppy seed in detail [7].
With time, the knowledge of the effects of opium spread globally from China and India to
Europe and eventually to the Americas [7]. In the 16th century, Paracelsus (1493–1541), a
Swiss-German physician-philosopher-alchemist-botanist, popularized the use of opium
as a general analgesic [7]. He developed alcoholic solutions of opium which he called
“Laudanum” (from Latin Laudare which means to praise) [7]. Laudanum (Figure 3) is
basically a tincture of opium containing about 10% of opium powder [7]. Through the
19th century, Laudanum and powdered opium were used globally for both medical and
recreational purposes. Medically, it was used as an analgesic and as a cough suppressant [7].
2.3. The Opium Wars
Recreational use of opium created a robust international opium trade. The opium
trade, however, led to conflicts between China and certain European countries, mostly
Great Britain [7]. The source of the conflict goes back to 1644, when the Chinese emperor,
Tsung Chen, banned the popular habit of smoking tobacco. Consequently, the Chinese
people turned to opium gradually as a desirable alternative [7]. By the 19 century, over
12 million Chinese were addicted to opium, and opium dens (Figure 4), as sites to buy and
sell opium, spread over the country [7]. Foreign merchants, especially the British, found
the soaring demand for opium in China a lucrative and profitable market [7]. By the 1830s,
the British East India Company supplied more than one million pounds of Indian opium
annually to China [7]. The Chinese authorities closed certain Chinese ports to the British in
an effort to stop the opium trade, which crippled the Chinese society [7]. This led to the
first (1836–1842) and second (1856–1860) opium wars between Great Britain and the Qing
dynasty of China [7]. The outcome of these wars was the defeat of China, which signed a
treaty to cede Hong Kong to Great Britain (which remained a territory up to 1999) and to
give British merchants free trading rights [7].
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Figure 4. Opium den and pipe. (A) Opium den and (B) pipe. Photographs are public domain.

2.4. Pharmacologic Discoveries and the Opioid Epidemic
After the opium wars were over, another major milestone emerged in the history of
opioids. This was the discovery that the acetylation of a compound may result in a new
compound more potent than its parent compound [7]. Thus, in 1874, the British scientist
C. R. Alder Wright acetylated morphine to produce diacetylmorphine, also known as
heroin [7].
By the early 20th century, laudanum was sold without a prescription and was a
constituent of many medicines [7]. Currently, laudanum is recognized as addictive and
is strictly regulated throughout most of the world. It is more commonly referred to as
a tincture of opium and is available as a prescription drug. The United States Uniform
Controlled Substances Act, for example, lists it as a Schedule II drug. Heroin, on the other
hand, was introduced for medical use in 1898, but by 1903, its abuse soared in the US.
Heroin use was made illegal by federal law in 1924.
Throughout the 20th century and early 21st century, there has been a beehive activity
in the production of semi-synthetic, synthetic, extended release and long-acting opioids.
The mechanism of the action of opioids was clarified and the use of opioids for diseases
associated with pain soared. However, the introduction of the concept of pain as the fifth
vital sign and the heavy marketing of certain opioids seem to be some of the reasons that
led to increased utilization of opioids that was, unfortunately, associated with the abuse
and misuse of opioids and the current opioid epidemic in the United States.
3. Classification of Opioids
Opioid analgesics are classified in several ways [9–16]. One classification divides them
according to their source as naturally occurring, semisynthetic and synthetic, as shown in
Table 1.
Physiologically, opioids are classified according to their binding and interaction with
specific receptors. Specifically, opioids are classified as agonists, partial agonists, mixed agonistantagonists and antagonists, as shown in Table 2 [17]. Another classification divides opioid
arbitrarily into weak and strong groups according to their potency and efficacy. Weak opioids
are available in combination with nonopioid analgesics, such as acetaminophen or aspirin. To
provide additive antipyretic and anti-inflammatory effects, they limit the amount that can be
administered, because a daily maximum of 4000 mg acetaminophen, an amount contained in
approximately 12 tablets of Percocet, is recommended to avoid hepatotoxicity.
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Table 1. Classification of opioids according to source.

Natural
Morphine, Codeine, Papaverine, Thebaine
Semi-synthetic
Heroin, Hydrocodone, Hydromorphone, Oxycodone,
Oxymorphone, Naloxone, Naltrexone, Nalmefene
Nalbuphine, Buprenorphine, Butorphanol
Synthetic
Meperidine, Fentanyl, Methadone, Levorphanol
Endogenous
Enkaphelin and Endorphin
Table 2. Classification of opioids according to chemical structure and function.

Agonists
Naturally occurring (opium alkaloids)
Codeine
Morphine
Papaverine
Semisynthetic opioids
Hydrocodone (Hycodan, Vicodin, Lortab, Tussionex)
Oxycodone (Percocet, Percodan, Roxicet, Roxicodone, Tylox, Oxycontin)
Hydromorphone (Dilaudid)
Oxymorphone (Numorphan **, Opana, Opana ER)
Synthetic opioids
Morphinans
Levorphanol (Levo-Dromoran)
Phenylpiperidines
Meperidine (Demerol, Pethidine)
Alfentanil and Remifentanil
Fentanyl (Sublimaze, Durgesic, Actiq, Fentora, Lazanda, Onsolis)
Sufentanil
Diphenylheptanes
Methadone (Dolophine)
Propoxyphene HCl (Darvon, Darvocet, Wygesic) *
Propoxyphene Napsylate (Darvon N) *
Partial agonists
Buprenorphine (Buprenex, Subutex, Butrans, Suboxone)
Dezocine (Dalgan) †
Mixed agonists-antagonists
Pentazocine (Talwin, Talwin NX)
Nalbuphine (Nubain **)
Butorphanol (Stadol †† )
Other
Tapentadol (Nucynta)
* Propoxyphene and all combination drugs containing it were withdrawn by the FDA in 2010, and other countries
are doing the same. Readers are advised to check its status in their countries. † Dezocine is not available in
the United States and Canada. However, in China, it is used after surgery. ** Brand has been discontinued
in the US. †† Metered spray and nasal forms of this drug have been discontinued in the US [17]. A relatively
recent classification is to divide opioids into short-acting and Extended Release and Long-Acting (ER/LA) [18].
Short-acting opioids are usually used for acute pain and ER/LA opioids for chronic pain [18]. In order to shift
from one opioid to another, equianalgesic potency has to be taken into consideration. One method of equianalgesic
dosing is shown in Table S1 [17].
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4. Pharmacodynamics of Opioids
Pharmacodynamics is the branch of pharmacology that studies the mechanisms of the
action of drugs and their biochemical and physiologic effects [19]. It is often referred to
as the branch of pharmacology that studies the effects of the drug on the body [19]. Most
drugs exert their effects via interactions with tissue receptors to which they are bound,
and hence, trigger a series of biochemical and physiologic cellular events that culminate
in a response characteristic of the drug in question [19]. This sequence of events can be
illustrated schematically as follows:
Drug + receptor → drug/receptor complex → response [17].
4.1. Mechanism of Action of Opioids
Opioid receptors are G protein-coupled receptors with exogenous and endogenous
opioids as ligands [20]. Opioid receptors were first discovered in the 1970s [21]. There
are three major types of opioid receptors, namely, µ, κ and δ, and eight subtypes of
these receptors, termed µ1, µ2, µ3, κ1, κ2, κ3, δ1 and δ2. Opioids interact with various
receptor subtypes. Adverse effects depend on the degree of binding to receptors. To
date, no known opioid analgesic selectively activates µ1 receptors without concomitant
activation of the other µ receptors. Such a drug would be ideal to produce analgesia
without sedation. Opioid analgesics that bind more to µ2 receptors, which mediate
sedation, and less to µ1 receptors, which mediate analgesia, might produce excessive
sedation without adequate analgesia, that is, a sleepy patient who complains of severe
pain whenever awakened. This situation could create logistical problems in managing
painful VOCs [17]. All opioid agonists bind primarily to µ receptors and less actively to
δ receptors. Buprenorphine is a partial agonist of µ receptors. Naloxone and Naltrexone
are antagonists to all receptors.
Elegant studies [22–26] have revealed a helical structure of the opioid receptors, which
forms pockets in which the corresponding ligand (opioid) fits snugly (Figure 5). Receptors
mediate two major functions, chemical recognition and physiologic action. Recognition
is highly specific, such that only L-isomers of opioids exert analgesic activity [27]. The
binding affinity, or strength with which a drug binds to its receptor, varies considerably
among opioids [28]. For example, fentanyl has a higher binding affinity than morphine [27].
The binding affinities of opioids appear to correlate well with their analgesic potencies [29].
Physiologically, by binding to receptors, opioids initiate a series of biochemical events,
including the activation of G proteins, inhibition of adenylate cyclase and extrusion of
potassium ions, resulting in hyperpolarization of cell membranes [30–32]; this delays or
prevents the transmission of painful stimuli.
The problem with the µ opioid receptors is that they transmit both the analgesic
effects and the side effects, especially the respiratory suppression. Attempts have been
made to design opioids that are “biased” toward activating painkilling signals only
while leaving the undesired side effects alone (Figure 6) [33]. To date, this approach has
been used in mouse models with questionable efficacy. Research in this line of studies
is ongoing.
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Table 3. Opioid risks.

1.

Mild/Moderate Side Effects:

•
•
•
•
•
2.

Serious Medical Side Effects:

•
•
•
•
3.

Sedation
Confusion
Nausea
Dizziness
Constipation

Gonadal suppression
Respiratory suppression
Sleep apnea
Dental complications

Serious Neurological and Behavioral Side Effects:

•
•
•
•
•
•
•

Physical dependence
Withdrawal
Tolerance
Hyperalgesia
Addiction
Pseudo addiction
Abuse, misuse, diversion

Adapted from Ballas, S.K. [35].

The chronic use of opioids causes hypogonadism, due to central suppression of the
hypothalamic secretion of gonadotropin-releasing hormone. Symptoms of opioid-induced
hypogonadism include menstrual irregularities and galactorrhea in women, impotence in
men, loss of libido, infertility, fatigue, anxiety, loss of muscle strength and mass, osteoporosis and compression fractures [36–39].
Dental Complications of Sickle Cell Disease include dental caries, dental erosions,
infractions, hypodontia, malocclusions, pulp necrosis, abnormal trabecular spacing and
infection [40].
Pulmonary effects include diminished tidal volume followed by depressed responses
of the respiratory center to carbon dioxide. Cardiovascular effects include depressed
responsiveness of α-adrenergic receptors, causing peripheral vasodilation, reduced peripheral resistance and inhibited baroreceptors, which may result in orthostatic hypotension.
Gastrointestinal effects include inhibition of peristalsis, which may cause constipation
and spasm of the sphincter of Oddi. Urinary tract manifestations are primarily urinary
retention due to enhanced bladder sphincter tone.
The excessive use of opioid analgesics may precipitate acute chest syndrome due
to their depressive effect on respiration. Recommendations to use nonsteroidal antiinflammatory drugs (NSAIDs) should be considered carefully [17]. Opioids have less
systemic side effects, and careful monitoring of their use ensures their safety. They should
be discontinued if the respiratory rate is ≤10 breaths per minute, and their adverse effects
can be quickly reversed with opioid antagonists. On the other hand, NSAIDs have more
systemic side effects that may not be readily obvious. For example, NSAIDs decrease the
levels of prostaglandins and prostacyclin, prostanoids that are essential in modulating
the vascular tone of smooth muscle and renal blood flow. Thus, NSAIDs may worsen the
clinical picture of ACS (Acute chest syndrome) due to their vasoconstrictive effects and
bronchospasm; NSAIDs are contraindicated in asthma for the same reasons. NSAIDs use
was associated with an increased risk of asthma exacerbation. In general, NSAID-induced
bronchospasm develops within 30 to 180 min (sometimes up to 24 h) after drug ingestion,
possibly precipitating the asthma exacerbation [41,42].
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Opioids have abuse potential; psychologic dependence or addiction, physical tolerance
and physical dependence may develop with repeated use. Other complications include
skin rash, itching and CNS (Central nervous system) hyperirritability, with toxic doses
manifesting in multifocal myoclonus and seizures. Meperidine is most notorious for the
latter complication; repetitive dosing results in the accumulation of the active metabolite
normeperidine, which produces hyperirritability, including seizures. However, seizures
can occur with toxic doses of most opioid analgesics [10,43].
Treatment of severe opioid withdrawal includes methadone plus clonidine either
orally (0.1–0.2 mg every 4–6 hours prn (Pro re nata)) or by using transdermal clonidine patch
0.1 mg daily. Other drugs that may be used to treat withdrawal include buprenorphine
plus naloxone orally [44,45]. The FDA approved oral lofexidine to treat the symptoms of
withdrawal [46]. Lofexidine is a structural analog of clonidine. Clinical trials comparing
the two medications showed comparable efficacy, though the severity of adverse events
was less than those with clonidine. This decreased risk for adverse effects could potentially
make lofexidine a safer option for detoxification [47–49].
Tolerance is defined as reduced potency of the analgesic effect of an opioid after
repeated administration or the need for higher doses to maintain the same result. It shifts
the dose-response curve to the right, indicating that a higher dose of opioids is required to
maintain the same level of analgesia [50]. The binding of an opioid to its receptor generates
a series of reactions that could culminate in tolerance [51]. Studies in mice have shown
that tolerance to morphine seems to be modulated by the gut-microbiome-central nervous
system interactions [52–54].
Management of opioid tolerance entails the use of N-Methyl-D-Aspartate (NMDA)
inhibitors. The NMDA channel is a complex structure [55]. It is both a receptor and a
calcium-gated channel [56,57]. Therapeutic inhibitors of NMDR include ketamine, clonidine, Lidocaine, dextromethorphan, nitrous oxide, zinc and methadone [51,58,59]. More recently, rosuvastatin, B vitamins and inhibition of platelet-derived growth factor-β (PDGFRβ) have been shown to attenuate or eliminate the development of tolerance to morphine in
rats and mice [60–63].
Dependence, also termed physical dependence, is a common and natural result of the
body growing used to a drug or medication, particularly an opioid such as morphine. If
the drug were suddenly stopped, the patient would undergo physical problems associated
with withdrawal (also termed abstinence syndrome). It is easily avoided by reducing the
dose of the drug gradually. It is distinct from addiction and tolerance.
Opioid-induced hyperalgesia (OIH) is defined as increased sensitivity to pain stimuli
(hyperalgesia) and pain caused by ordinarily nonpainful stimuli (referred to as allodynia).
Typically, hyperalgesia is noted in parts of the body different from the site of the original
pain complaint, and the descriptors of the pain change with some similarity to certain
aspects of neuropathic pain, such as burning sensation. Unlike tolerance, OIH worsens
with higher doses of opioids [64–66].
The pathophysiology of OIH is not well understood. A proposed mechanism is the
activation of the NMDA receptor [64,67]. This activation results in calcium influx, which in
turn enhances the excitability of neurons, which facilitates further transmission of painful
stimuli [59].
Management of OIH involves weaning from opioids, opioid rotation and the use
of NMDA inhibitors such as methadone, clonidine, Lidocaine or ketamine, as needed.
Weaning and rotation are usually done together.
Pseudoaddiction is a syndrome of behavior and attitudes that emerges in patients
who are not being provided with adequate analgesics.
Physical dependence, addiction, tolerance and hyperalgesia may become confused
by health care providers and used interchangeably because these conditions may occur
together in the active drug abuser. Drug-seeking behavior is rare in patients with SCD
taking opioids under medical supervision, and the incidence of iatrogenic addiction is
low [68,69].
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5. Pharmacokinetics of Opioids
Pharmacokinetics is the branch of pharmacology that studies the factors affecting
drug movement in the body. Unlike pharmacodynamics, the focus of pharmacokinetics
is the effects of the body on the drug including absorption, distribution, metabolism and
excretion [19].
5.1. Metabolism of Opioids
The metabolism of opioids includes two major phases shown in Table 4 [17,70]. Phase I
involves the cytochromes P450 (CYPs) enzymes, whereas glucoronidation is the major
metabolic pathway in phase II metabolism.
Table 4. Metabolic pathways of commonly used opioids in sickle cell disease.
Opioid

Phase I
CYP450

Phase II
Glucuronidation

Active Metabolite

Inactive
Metabolite

Non-Opioid
Active Metabolite

Morphine

None

Yes

Hydromorphone

Normorphine

M6G, M3G

Hydromorphone

None

Yes

None

Minor Metabolites

HM3G

Oxymorphone

None

Yes

None

Oxy3G

6-OHOxymorphone

Codeine

CYP2D6

None

Morphine,
Hydrocodone

Norcodeine

None

Hydrocodone

CYP2D6, 3A4

None

Hydromorphone

Norhydrocodone

None

Oxycodone

CYP2D6, 3A4

None

Oxymorphone

None

Noroxycodone

Fentanyl

CYP3A4

None

None

Norfentanyl

None

Methadone

CYP2D6, 3A4, 2C8,
2C9, 2C19,2B6, 1A2

None

None

Tramadol

CYP2D6, 3A4, 2B6

None

None

2-C2H5-5-CH33,3diphenypyrrolidine
Nortramadol

None
O-desmethyltramadol

M6G = Morphine-6-glucuronide; M3G = Morphine-3-glucuronide; HM3G = Hydromorphone-3-glucuronide; Oxy3G = Oxymorphone
-3-glucuronide.

The CYP superfamily is a large and diverse group of enzymes that catalyze the oxidation of organic substrates, including metabolic intermediates such as lipids and steroid
hormones, drugs and toxic chemicals. Human CYP consists of 21 currently described families and 20 subfamilies coded by 57 genes. The CYP isoforms 1, 2 and 3 are responsible for
the majority of hepatic drug metabolism [17]. Of these, CYP2C9 and CYP2D6 are involved
in the metabolism of several drugs used for pain control including opioid and nonopioid
analgesics. Phase I metabolism of opioids involves primarily the CYP3A4 and CYP2D6
enzymes. The CYP3A4 enzyme metabolizes more than 50% of all drugs; consequently,
opioids metabolized by this enzyme have a high risk of drug–drug interactions [17,70].
Thus, medications used in addition to opioids may enhance or inhibit the metabolism of
the opioid in question.
A major issue in the pharmacogenomics of the CYP 450 system is that the enzymes
may be deleted, mutated, duplicated or even triplicated. The genotypes of the CYP 450
are categorized into phenotypes based on the activity of the variant enzymes. Ultrarapid
metabolizers (UMs) have greater-than-normal activity due to duplication or triplication, of
active alleles [71,72], extensive metabolizers (EMs) have normal enzyme activity, intermediate metabolizers (IMs) have decreased enzyme activity and poor metabolizers (PMs) have
absent or little enzyme activity. Thus, the metabolic activity of a certain enzyme could be
normal (function 100%), intermediate (function 50%), poor (function 0–10%) or ultrarapid
(function >100%). The clinical effects of CYP2D6 allelic variants are best demonstrated
with codeine administration. Patients who are poor opioid metabolizers experience reduced efficacy with codeine because of their limited ability to metabolize codeine to its
active metabolite morphine. In contrast, patients who are ultrarapid opioid metabolizers
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may experience increased opioid effects with a usual dose of codeine because their rapid
metabolism generates a high concentration of morphine [17].
Phase II metabolism involves morphine, where it mostly undergoes glucuronidation.
Moreover, morphine metabolism is subject to genetic variability due to allelic variants in
a number of genes. Variations in these genes may explain the variability in efficacy and
potency of morphine in patients with SCD and in patients with other pain syndromes. Most
important among these include the uridine diphosphate glucuronyltransferase enzyme
(UGT2B7, located on chromosome 4q13), the µ-opioid receptor 1 gene (OPRM1; located on
chromosome 6q24–q25) and catechol-O-methyltransferase (COMT; located on chromosome
22q11.21). The presence of the UGT2B7 promoter variant—840 G→A is reported to decrease
morphine glucuronidation in patients with SCD [17]. The frequency of this allele among the
20 patients with SCD studied was 70%. In comparison, the UGT2B7 promoter variant—79
G→A has no effect on morphine glucuronidation.
The OPRM1 gene encodes a µ-opioid receptor belonging to the G protein-coupled
membrane receptor family [17]. An allelic variant of OPRM1, 118 A→G, has been implicated in lowering the potency of morphine and the level of M6G in patients with the A/G
genotype. Patients homozygous for the G allele (GG) required larger doses of morphine to
achieve pain relief [17].
In addition, the pharmacokinetics of morphine in patients with SCD appears to differ
from that in patients with other pain syndromes. Studies of children with SCD treated
with intravenous morphine during painful VOC found increased clearance of morphine,
particularly in prepubertal children [17], which was significantly greater than that in studies
conducted in children with postoperative pain or cancer pain [17]. Similarly, increased
clearance of morphine was reported in young adults (≥18 years) with SCD in a steady
state in the absence of painful VOC [17].
5.2. Drug–Drug Interactions
Patients with sickle cell pain often receive a combination of various drugs, including
opioid analgesics, nonsteroidal anti-inflammatory drugs (NSAIDs), adjuvant analgesics
and antibiotics.
Such drugs may interact, and the response elicited may be equal to, greater than or
less than the sum of the effects of the individual compounds. Synergism, potentiation,
additive effect and antagonism are some of the common terms that describe the pattern of
drug–drug interactions [17].
Coadministration of other drugs with opioid analgesics requires skillful selection
and monitoring, especially when a centrally acting drug is used. The sedative effects
of an opioid may accentuate that of other agents such as antidepressants, neuroleptics
and anxiolytics. Drugs with anticholinergic effects may worsen constipation caused by
opioids [43,73,74].
Generally, the effects of morphine can be antagonized by acidifying agents and potentiated by alkalinizing agents. The concomitant use of anticholinergics with opioids, including
morphine, may result in an increased risk of severe constipation and urinary retention.
Central nervous system depressants, such as other opioids, alcohol, anesthetics, antihistamines, barbiturates, β-adrenergic blocking agents, chloral hydrate, glutethimide,
hypnotics, monoamine oxidase inhibitors, phenothiazines, pyrazolidone, sedatives, skeletal
muscle relaxants and tricyclic antidepressants, can enhance the depressant effects of morphine. Concurrent use may result in potentiation of CNS depression, and death may occur.
If used concurrently with CNS depressants, dosage adjustment may be required [43,73,74].
Amphetamines potentiate the analgesic effect of opioids. Opioids can increase the
anticoagulant activity of warfarin and other anticoagulants.
5.3. The Opioid Epidemic and the Use of Opioids in SCD
The advent of the opioid epidemic had a negative effect on the management of
sickle cell pain. Some providers found the opioid epidemic a justification to minimize
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the use of opioids for sickle cell pain. Alternatives to opioids for sickle cell pain are not
available yet. The status of cannabinoids is unsettled and Kratom failed as replacements
to opioids [75,76]. The systemic side effects of NSAIDs in adults such as renal failure,
cardiovascular compromise and gastrointestinal bleeding are worse than the systemic
side effects of opioids [17]. The major cause of death in SCD is not opioids [77] but the
complications of the disease such as infection, acute chest syndrome, renal failure, stroke
and multiorgan failure. In addition, the use of opioids by patients with SCD remained
constant over the years [78].
6. Conclusions
Currently, there is a plethora of opioid preparations on the market, especially in the
USA. Opioids come in different formulations, shapes, sizes, doses, tablets, capsules, fluids,
patches or inhalers. They are among the best pain relievers and, unfortunately, the worst
drugs that are amenable for misuse associated with high mortality. Thus, the problem with
opioids is not the drugs themselves but the way they are used. Fortunately, opioids seem
to be used wisely by the majority of the providers who treat patients with SCD. Mortality
in patients with SCD is primarily due to the complications of the disease itself and not the
opioids. Issues that are not finalized in SCD pertain to determining the best opioid(s) to
manage acute, chronic, neuropathic pain as well as other types of pain. The most commonly
used opioid in SCD changed with time. In the late 20th century, meperidine was used most
commonly. Later, this was replaced by morphine, hydromorphone and fentanyl. Currently,
buprenorphine seems to be on the rise to be the best to treat acute and chronic sickle cell
pain, and in combination with Naloxone, it is the best to prevent and treat addiction and
withdrawal.
Supplementary Materials: The following are available online at https://www.mdpi.com/2077-038
3/10/3/438/s1, Table S1: Equianalgesic dosing equivalents of opioids in opioid-naïve patients.
Funding: This research received no external funding.
Conflicts of Interest: The author declares no conflict of interest.
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